NEW YORK and AMSTERDAM, Oct. 16, 2025 – atai Life Sciences (NASDAQ: ATAI) (“atai” or “Company”), a clinical-stage biopharmaceutical firm dedicated to revolutionizing mental health disorder treatments, today announced the pricing of a registered underwritten public offering for 23,725,000 common shares, set at $5.48 per share. The company has granted the underwriters a 30-day option to acquire up to an additional 3,558,750 common shares at the public offering price, less the underwriting discount. atai will be the sole seller of all common shares in this offering.
The gross proceeds from this offering, before accounting for underwriting discounts, commissions, and other offering expenses payable by atai, are anticipated to be approximately $130 million. atai intends to utilize the net proceeds from this offering, in conjunction with its existing cash, cash equivalents, and short-term investments, to further the clinical development of its product candidates and programs, as well as for general corporate purposes and working capital.
The offering is projected to conclude on October 20, 2025, pending customary closing conditions.
Jefferies LLC is serving as the lead bookrunner for the offering. Berenberg Capital Markets LLC is also acting as a passive bookrunner. Oppenheimer & Co. Inc. and Canaccord Genuity LLC are participating as co-managers for the offering.
The securities in the aforementioned underwritten offering are being presented pursuant to an effective shelf registration statement, which was filed with the U.S. Securities and Exchange Commission (“SEC”) on September 29, 2025, and automatically became effective upon filing. This offering is being made exclusively by means of a prospectus supplement and its accompanying prospectus, which together form part of the effective shelf registration statement. A final prospectus supplement relating to the offering will be filed with the SEC and made available on the SEC’s website at www.sec.gov. When available, copies of the final prospectus may be obtained by contacting: Jefferies LLC, Attention: Equity Syndicate Prospectus Department, 520 Madison Avenue, New York, New York 10022, or by telephone at 877-821-7388, or by e-mail at Prospectus_Department@jefferies.com; Berenberg Capital Markets LLC, Attention: Investment Banking, 1251 Avenue of the Americas, 53rd Floor, New York, New York 10020, or by telephone at +1 (646) 949-9000, or by e-mail at prospectusrequests@berenberg-us.com; Oppenheimer & Co. Inc., Attention: Syndicate Prospectus Department, 85 Broad Street, New York, New York 10004, or by telephone at (212) 667-8055, or by e-mail at EquityProspectus@opco.com; or Canaccord Genuity LLC, Attention: Syndication Department, 1 Post Office Square, 30th Floor, Boston, Massachusetts 02109, or by e-mail at prospectus@cgf.com.
This press release should not be construed as an offer to sell or a solicitation of an offer to purchase, nor will there be any sale of these securities in any state or jurisdiction where such an offer, solicitation, or sale would be unlawful without prior registration or qualification under the securities laws of that state or jurisdiction.
About atai Life Sciences
atai is a clinical-stage biopharmaceutical company focused on developing highly effective treatments for mental health disorders to significantly improve patient outcomes. Its pipeline of psychedelic-based therapies includes BPL-003 (intranasal mebufotenin benzoate) for treatment-resistant depression (TRD), which is being advanced through a strategic investment and planned strategic combination with Beckley Psytech Limited; VLS-01 (buccal film DMT), also for TRD; and EMP-01 (oral R-MDMA) for social anxiety disorder. All three programs are currently in Phase 2 clinical development. atai is also progressing a drug discovery program aimed at identifying novel, non-hallucinogenic 5-HT2AR agonists for both TRD and opioid use disorder. These programs are designed to address the intricate nature of mental health by providing commercially scalable interventional psychiatry therapies that can be smoothly integrated into healthcare systems.
Forward-looking Statements
This press release contains forward-looking statements as defined by the Private Securities Litigation Reform Act of 1995, specifically Section 27A of the Securities Act and Section 21E of the Securities Exchange Act of 1934, as amended. Such forward-looking statements include, but are not limited to, uncertainties regarding the completion of the public offering, the granting of the option to purchase additional shares, the anticipated use of proceeds from the offering, and other statements related to the proposed offering. Numerous risks and uncertainties exist that could cause actual results and atai’s plans and objectives to differ materially from those expressed in the forward-looking information, including those risks discussed in the section titled “Risk Factors” in atai’s most recent Annual Report on Form 10-K and Quarterly Reports on Form 10-Q, in each case, as filed with the SEC, and future reports to be filed with the SEC. These documents contain and identify important factors that could lead atai’s actual results to differ materially from those contained in atai’s forward-looking statements. Any forward-looking statements in this press release are valid only as of the date hereof, and atai expressly disclaims any obligation to update any forward-looking statement, except as required by law. These forward-looking statements should not be relied upon as representing atai’s views as of any date subsequent to the date of this press release.
Contact Information
Investor Contact:
Media Contact:
